Award disclosed
Eric H. L. So
Director
Common Shares
- Value context
- Unavailable
- Reported price
- Price not reported
Loading data…Scanning SEC filings…Checking Congress reports…Following the signal…
Helus Pharma Inc.
Last 30 daysInsiders bought $8.42M · 4 buyers, led by Eric H. L. So (Executive Chair) with $3.57M. No qualifying insider sales.
Showing the first 6 of 11 trades on this page.
Director
Common Shares
Chief Financial Officer
Common Shares
$6,901,848 of common-equity purchase value after transaction-age decay across 180 days.
4 distinct reporting-owner group(s). Joint rows count once; identity is not proof of discretion.
Qualifying common-equity P acquisition; no disclosed plan, exercise or excluded purchase context detected.
Qualifying common-equity P acquisition; no disclosed plan, exercise or excluded purchase context detected.
4 buying groups inside 30 transaction-date days, public by the snapshot cutoff.
At least one row increased reported same-security holdings by 10% or established a new reported position; indirect interests may overlap.
This score describes qualifying insider purchases at issuer level. Read the methodology
Open a transaction's SEC filing for the primary evidence. A code P may describe an open-market or private purchase; classification is not proof of intent.
Insider activity can have many explanations. Signal Strength is not a probability of profit or a recommendation to trade.
Chief Growth Officer
Common Shares
Chief Executive Officer
Common Shares
Chief Growth Officer
Common Shares
Chief Growth Officer
Related filings are retained as evidence. This economic transaction is counted once.
This record is excluded from totals to avoid counting the same transaction twice.
Canonical SEC filing ↗Original transaction filing ↗Common Shares
Excluded from the common-share buying signal. See trade details.
Executive Chair
Common Shares
Executive Chair
Common Shares
Chief Growth Officer
Common Shares
Executive Chair
Common Shares
Chief Growth Officer
Common Shares
| Reporting insider | Security / transaction | Amount / price | Value | Traded / disclosed | Source |
|---|---|---|---|---|---|
| Director | Common SharesGrant or award | 248,000Price not reported | Unavailable | Sep 30Filed Oct 1 · 1d later | SEC filing |
| Chief Financial Officer | Common SharesPurchase | 3,000$12.91 / share | $38.73K | Sep 29Filed Oct 1 · 2d later | SEC filing |
| Chief Growth Officer | Common SharesGrant or award | 248,000Price not reported | Unavailable | Sep 30Filed Oct 1 · 1d later | SEC filing |
| Chief Executive Officer | Common SharesPurchase | 100,000$13.47 / share | $1.35M | Sep 21Filed Sep 21 · 0d later | SEC filing |
| Chief Growth Officer | Common SharesPurchase | 100,000$12.47 / share | $1.25M | Sep 8Filed Sep 11 · 3d later | SEC filing |
Chief Growth OfficerAlso reported in another filingRelated filings are retained as evidence. This economic transaction is counted once. This record is excluded from totals to avoid counting the same transaction twice. Canonical SEC filing ↗Original transaction filing ↗ | Common SharesPurchaseExcluded from purchase score | 100,000$12.47 / share | Unavailable | Sep 8Filed Sep 11 · 3d later | SEC filing |
| Executive Chair | Common SharesPurchase | 100,000$12.39 / share | $1.24M | Sep 8Filed Sep 11 · 3d later | SEC filing |
| Executive Chair | Common SharesPurchase | 100,000$12.09 / share | $1.21M | Sep 4Filed Sep 10 · 6d later | SEC filing |
| Chief Growth Officer | Common SharesPurchase | 100,000$11.78 / share | $1.18M | Sep 3Filed Sep 10 · 7d later | SEC filing |
| Executive Chair | Common SharesPurchase | 95,000$11.81 / share | $1.12M | Sep 1Filed Sep 9 · 8d later | SEC filing |
| Chief Growth Officer | Common SharesPurchase | 90,000$11.59 / share | $1.04M | Aug 31Filed Sep 9 · 9d later | SEC filing |
This reflects the filings imported so far, not a complete trading history.